Navigation Links
Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
Date:6/2/2009

nt of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(R) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleos(t)ide analogs, a class of compounds which act to inhibit the enzymes required for viral replication. We currently have three clinical-stage product candidates: R7128, a nucleoside analog for chronic HCV infections, has initiated a Phase 2b clinical trial in combination with Pegasys plus Copegus through a strategic collaboration with Roche; PSI-7851, an unpartnered, next generation HCV nucleotide analog, which recently began Phase 1 clinical studies and Racivir, for the treatment of HIV that has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
2. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
3. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
4. Pharmasset Reports Fiscal Year End 2008 Financial Results
5. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
6. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
7. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
8. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
9. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
10. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... HERTFORDSHIRE, England and PITTSBURGH ... (NASDAQ: MYL ) today announced that its ... Company plc (NYSE: PRGO ; TASE) and ... Perrigo,s shareholders at an extraordinary general meeting of ... of two-thirds of the votes cast at the extraordinary general ...
(Date:8/28/2015)... LONDRES, 28 de agosto de 2015   ... su participación en el  Congreso de la ESC ... más recientes y novedosas, entre ellas HeartModel A.I. ... las personas y la tecnología con los protocolos ... guiar los tratamientos y permitir atención en el ...
(Date:8/27/2015)... ALEXANDRIA, Va. , Aug. 27, 2015 /PRNewswire-USNewswire/ ... in the Food and Drug Administration,s (FDA,s) draft ... including reference products and biosimilars, to bear a ... years, AMCP has been seeking a decision from ... joined 18 diverse health care stakeholders urging the ...
Breaking Medicine Technology:Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2
... and WILMINGTON, Del., Dec. 21 Eli Lilly and ... (Nasdaq: INCY ) announced today that they have ... for the development and commercialization of Incyte,s oral JAK1/JAK2 ... and autoimmune diseases. The lead compound, INCB28050, is currently ...
... , CARLSBAD, Calif., Dec. 21 Isis ... will receive a $10 million payment from OncoGenex Pharmaceuticals, Inc. ... license of OGX-011 to Teva Pharmaceutical Industries Ltd. ( TEVA). ... and OncoGenex that has completed a successful Phase 2 program ...
Cached Medicine Technology:Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies 2Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies 3Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies 4Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies 5Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies 6Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva 2Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva 3
(Date:8/30/2015)... ... August 31, 2015 , ... Intellitec Solutions, ... Convention & Expo October 5th & 6th in San Antonio, TX. Dedicated to ... brings industry professionals from all over the country come to share the latest ...
(Date:8/30/2015)... ... , ... Lizzie’s Lice Pickers , a company that offers professional live ... offering lice head checks for just $10, which is a significant discount from the ... their lice treatment products. “With kids returning to school, it is very important to ...
(Date:8/30/2015)... ... August 30, 2015 , ... Nutritional Products International ( ... expansion of global cosmeceutical and skin care brands. Mr. Fernandez comes with ... 25 years working in operations, purchasing and management for some of the nations ...
(Date:8/29/2015)... VA (PRWEB) , ... August 30, 2015 , ... ... Webinar**, Sept. 15, 2015 — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent ... more than a simple digital handwritten signature. , Clinical trial sites ...
(Date:8/29/2015)... , ... August 29, 2015 , ... Dr. Tim Novelli, ... His mission is to increase acceptance of the chiropractic field in the military. ... further debilitate them. Although Chiropractic was made available to the VA program over ...
Breaking Medicine News(10 mins):Health News:Intellitec Solutions to feature Microsoft Dynamics GP at AHCA/NCAL 66th Annual Convention & Expo 2Health News:Lizzie’s Lice Pickers Announces Back to School Head Check Special and Discounted Lice Treatment Products 2Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2
... parents worry babies get ,too much too soon, but ... May 24 (HealthDay News) -- Some American parents are ... they,re worried that their infants are getting too many ... issues. , The issue has been especially persistent when ...
... ... project management support and peer-to-peer learning opportunities to aid in transformation process, ... Leawood, ... Physicians, today announced a new service offering aimed at helping small primary care ...
... Knowledge regarding environmental factors influencing the risk of ... this area. In particular, the roles of smoking and ... this month in the Journal of Alzheimer,s Disease ... the risk of Alzheimer,s disease, particularly in women who ...
... ... new facility , ... (Vocus) May 24, 2010 -- AthletiCo Physical and Occupational Therapy announces the relocation ... The new facility is located in the Hillcrest Center across the street from the Worden ...
... ... ... InPro Corporation announced it has joined the American Academy of Healthcare Interior Designers (AAHID) ... certifies the knowledge, skills and abilities of healthcare interior designers. Board Certified Healthcare Interior ...
... ... its expansion into new office space in the Century Square building in downtown Seattle, Washington. ... Vancouver, B.C., supports a number of employees on the East Coast and in the Midwest ... ...
Cached Medicine News:Health News:No Benefit Seen in Delaying Infant Vaccinations 2Health News:No Benefit Seen in Delaying Infant Vaccinations 3Health News:TransforMED Launches New Service Offering to Accelerate Medical Home Adoption in Small Practices 2Health News:TransforMED Launches New Service Offering to Accelerate Medical Home Adoption in Small Practices 3Health News:TransforMED Launches New Service Offering to Accelerate Medical Home Adoption in Small Practices 4Health News:AthletiCo's Champaign-Urbana Physical Therapy Center Relocates to 2040 S. Neil in Champaign 2Health News:AthletiCo's Champaign-Urbana Physical Therapy Center Relocates to 2040 S. Neil in Champaign 3Health News:InPro Becomes AAHID Industry Partner 2Health News:Quorum Review IRB Commemorates New Office with Ribbon Cutting Ceremony 2
... 64 is the ultimate CT solution ... Our system fuses the latest and ... applications delivering unprecedented image quality. It ... to meet the requirements for cardiac ...
... MONO-plus test uses direct ... the qualitative detection of ... whole blood, serum or ... waived whole blood kit ...
One inch disposable patch electrode uses a specially formulated adhesive solid gel. Reusable lead wire with snap connector provides economic benefits. Ideal for sleep studies where leg movement or EK...
... Made with elastic fabric, these head cap ... need to begin testing. Each Electro-Cap System ... the International 10-20 System. When you place ... are using with your head cap system ...
Medicine Products: